Originally doing business as Quark Biotech and renamed in 2007, Quark Pharmaceuticals, Inc. is working in field of Endpoint Driven Drug Development (ED3) efficiently to develop superior therapeutics to treat complex diseases. ED3 is a vertically integrated drug development approach that starts with defining a desired clinical endpoint in any specified disease, to identify drug candidates that achieve the desired endpoint. The Company is currently focused on therapeutics to treat metabolic disorders, cancer, and cardio/renal diseases.. Quark devoted its early years to developing its innovative technology platform for identification of novel functional target genes and proteins. The basic concept, patented by Quark, of high throughput gene inactivation combined with microarray detection of the functional genes responsible for the occurrence of phenotypes of interest, was at that time revolutionary. With the advent of siRNA technology, Quarkâs approach is rapidly becoming the technology of choice for functional studies industry-wide. The firm applied their BiFAR platform in gene discovery programs in serious diseases with significant unmet medical needs, often in collaboration with large pharmaceutical partners and are now harvesting the fruits of the innovative targets and concepts identified.
